NO20074065L - Farmakogenomiske markorer for prognose av faste tumorer - Google Patents

Farmakogenomiske markorer for prognose av faste tumorer

Info

Publication number
NO20074065L
NO20074065L NO20074065A NO20074065A NO20074065L NO 20074065 L NO20074065 L NO 20074065L NO 20074065 A NO20074065 A NO 20074065A NO 20074065 A NO20074065 A NO 20074065A NO 20074065 L NO20074065 L NO 20074065L
Authority
NO
Norway
Prior art keywords
prognosis
patients
solid tumors
gene
cci
Prior art date
Application number
NO20074065A
Other languages
English (en)
Norwegian (no)
Inventor
Andrew J Dorner
Natalie Constance Twine
William L Trepicchio
Donna K Slonim
Frederick Immermann
Michael E Burczynski
Andrew Strahs
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20074065L publication Critical patent/NO20074065L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20074065A 2005-02-18 2007-08-07 Farmakogenomiske markorer for prognose av faste tumorer NO20074065L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65408205P 2005-02-18 2005-02-18
PCT/US2006/005772 WO2006089185A2 (en) 2005-02-18 2006-02-17 Pharmacogenomic markers for prognosis of solid tumors

Publications (1)

Publication Number Publication Date
NO20074065L true NO20074065L (no) 2007-11-14

Family

ID=36649050

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074065A NO20074065L (no) 2005-02-18 2007-08-07 Farmakogenomiske markorer for prognose av faste tumorer

Country Status (15)

Country Link
US (1) US20090061423A1 (pt)
EP (1) EP1849007A2 (pt)
JP (1) JP2008529554A (pt)
KR (1) KR20070115891A (pt)
CN (1) CN101120255A (pt)
AU (1) AU2006214078A1 (pt)
BR (1) BRPI0608429A2 (pt)
CA (1) CA2598393A1 (pt)
CR (1) CR9298A (pt)
IL (1) IL185206A0 (pt)
MX (1) MX2007010001A (pt)
NO (1) NO20074065L (pt)
RU (1) RU2007129864A (pt)
WO (1) WO2006089185A2 (pt)
ZA (1) ZA200706919B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101446626B1 (ko) * 2005-09-02 2014-10-06 도레이 카부시키가이샤 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법
US20100222230A1 (en) * 2007-04-11 2010-09-02 The General Hospital Corporation Diagnostic and prognostic methods for renal cell carcinoma
AU2015202116B2 (en) * 2010-01-11 2017-06-08 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX375138B (es) 2010-01-11 2025-03-06 Genomic Health Inc Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal.
US10181008B2 (en) 2013-05-30 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
JP6427750B2 (ja) * 2013-10-02 2018-11-28 コニカミノルタ株式会社 Ｃｘｃｌ１、ならびにｓｍｏｘおよび／またはｉｄ１の発現量に基づく肺癌患者の予後を判定するためのデータ収集方法およびキット
US20180044736A1 (en) * 2015-02-03 2018-02-15 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
EP3274467A4 (en) * 2015-03-24 2018-10-31 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
CN111537424B (zh) * 2020-04-26 2022-10-28 北京市神经外科研究所 基于外周血细胞评估脊髓胶质瘤患者预后性的系统
CN111640518A (zh) * 2020-06-02 2020-09-08 山东大学齐鲁医院 一种宫颈癌术后生存预测方法、系统、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076735A1 (en) * 1998-09-25 2002-06-20 Williams Lewis T. Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells
JP3944996B2 (ja) * 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
EP1356114A2 (en) * 2001-01-31 2003-10-29 Whitehead Institute For Biomedical Research Brain tumor diagnosis and outcome prediction
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
CA2505416A1 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors

Also Published As

Publication number Publication date
CN101120255A (zh) 2008-02-06
RU2007129864A (ru) 2009-03-27
CR9298A (es) 2007-11-23
WO2006089185A3 (en) 2006-09-28
WO2006089185A8 (en) 2007-09-27
EP1849007A2 (en) 2007-10-31
CA2598393A1 (en) 2006-08-24
BRPI0608429A2 (pt) 2009-12-29
ZA200706919B (en) 2008-06-25
WO2006089185A2 (en) 2006-08-24
IL185206A0 (en) 2008-01-06
AU2006214078A1 (en) 2006-08-24
US20090061423A1 (en) 2009-03-05
KR20070115891A (ko) 2007-12-06
MX2007010001A (es) 2007-09-27
JP2008529554A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
NO20074065L (no) Farmakogenomiske markorer for prognose av faste tumorer
WO2019195268A3 (en) Methylation markers and targeted methylation probe panels
Chowdhry et al. Myxoid liposarcoma: treatment outcomes from chemotherapy and radiation therapy
MX2015005448A (es) Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2).
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
MY183402A (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
Krabbe et al. Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: results of a current series and a review of the literature
HK1258091A1 (zh) 用於发现预测对检查点抑制剂敏感的 msi 和新表位的系统、组合物和方法
MX384679B (es) Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl).
EP4246144A3 (en) Compositions and methods for screening mutations in thyroid cancer
WO2011027308A8 (en) Novel tumor markers
EP4435112A3 (en) Compositions and methods for screening solid tumors
BR112014032728A2 (pt) uso de marcadores no diagnóstico e tratamento de câncer de próstata
ATE492651T1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
Itchins et al. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre
WO2011163627A3 (en) Organ specific diagnostic panels and methods for identification of organ specific panel proteins
CL2008000356A1 (es) Compuestos derivados de 4-amino quinazolina, capaces de inhibir la transduccion de senales a traves de pirosina quinasa; composicion farmaceutica que comprende uno de los compuestos; y procedimiento para preparar la composicion farmaceutica y los compuestos, utiles en el tratamiento tumores y enfermedades de las vias respiratorias y pulmonares.
BRPI0518036A (pt) métodos e sistemas para prognóstico e tratamento de tumores sólidos
WO2011027311A3 (en) Novel tumor markers
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata
MX2011007989A (es) Marcadores para predecir y verificar la respuesta a terapia de inhibidor de aurora cinasa b.
WO2007023191A3 (de) Polypeptidmarker zur diagnose von blasenkrebs
Gaya et al. Is there a limit for the laparoscopic approach of a retroperitoneal residual mass postchemotherapy?
Goldner et al. Is the Roach formula predictive for biochemical outcome in prostate cancer patients with minimal residual disease undergoing local radiotherapy after radical prostatectomy?

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application